Wednesday, July 02, 2025

GET OUR FREE E-NEWSLETTER

“You may choose to look the other way, but you can never say again that you did not know.”

— William Wilberforce

Search

FDA Approves Yeztugo as Injectable Product to Prevent HIV in Adults and Adolescents

FDA Approves Yeztugo as Injectable Product to Prevent HIV in Adults and Adolescents

Last week, Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo (lenacapavir), the company’s injectable HIV-1 capsid inhibitor, for use as pre-exposure prophylaxis (PrEP). Yeztugo is not labeled a “vaccine” but is a pharmaceutical product intended to reduce the risk of acquiring human immunodeficiency virus (HIV) via sexual activity […]

FDA Approves Novavax’s COVID-19 Vaccine With Restrictions

FDA Approves Novavax’s COVID-19 Vaccine With Restrictions

On May 16, 2025, the U.S. Food and Drug Administration (FDA) approved licensure of Novavax, Inc.’s Nuvaxovid protein-based COVID-19 vaccine, which has been available in the United States under Emergency Use Authorization (EUA) since July 2022.1 The decision for a full licensure was postponed while  the new agency leadership under the current administration conducted a […]

FDA, CDC Halt Use of Chikungunya Vaccine in Adults 60+ After Two Deaths Reported

FDA, CDC Halt Use of Chikungunya Vaccine in Adults 60+ After Two Deaths Reported

On May 9, 2025, the U.S. Food and Drug Administration (FDA) and the  U.S. Centers for Disease Control and Prevention (CDC) recommended a temporary pause in the use of Ixchiq, a live virus vaccine designed to prevent chikungunya virus infection, in adults aged 60 years and older. The recommendation follows reports of serious post-marketing adverse […]

Guillain-Barré Syndrome Warning Added to Shingrix Vaccine in Australia

Guillain-Barré Syndrome Warning Added to Shingrix Vaccine in Australia

In February 2024, Australia’s Therapeutic Goods Administration (TGA), the country’s national regulatory authority for drugs and, initiated an investigation into a potential association between GSK plc’s Shingrix shingles vaccine, Guillain-Barré syndrome (GBS), which causes inflammation and damage to the nerves, that may include paralysis.1 The investigation was prompted by two reports of GBS following Shingrix […]

Pfizer Ends Development of Weight-Loss Pill After Liver Injury in Trial Participant

Pfizer Ends Development of Weight-Loss Pill After Liver Injury in Trial Participant

Pfizer, Inc. announced that it is discontinuing development of its experimental daily weight loss pill after a trial participant suffered a liver injury potentially linked to the drug. The company confirmed that the oral GLP-1 drug, danuglipron (PF-06882961), is no longer in development following the incident.1 Pfizer has been studying danuglipron since 2022.2 A Pfizer […]

Search in Site

To search in site, type your keyword and hit enter

Search
The Vaccine Reaction
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.